RIBOZYME AND OMICS
2017 - 2022
Selected as a military service-designated entities(research institute)
US FDA IND(phase 1/2a) approval of RZ-001(HCC)
관련기사보기Wins Award for Promising Candidates for Genetic Therapy at International Events
관련기사보기Series C funding complete
관련기사보기Clinical test phase-1/2a of RZ-001 approved by Korean MDFS
관련기사보기INNOBIZ Certification acquired
RZ-001 (HCC treatment) Patent granted (JP)
Selected as the national new drug development project announced by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, Ministry of health and Welfare
관련기사보기RZ-003 (Alzheimer’s disease treatment) Patent granted (KR)
RZ-001 (HCC treatment) Patent granted (KR)
RZ-001 (HCC treatment) Patent granted (US)
Bridge funding complete
관련기사보기Selected for Phase 2 of Innovativ drug pipeline discovery by the Ministry of Science and ICT
관련기사보기Successful completion of TIPS program selected by Ministry of SMEs and Startups
Participate in Innovative drug pipeline project of Ministry of Science and ICT
Head Office relocated from Gwangju to Yongin (Dankook Univ.)
Opening Ceremony of Rznomics Inc. (Oct 2, 2019)
Series A investment completed
관련기사보기Selected for Innovative drug pipeline discovery project by the Ministry of Science and ICT
Korean Venture Capital Association corporate certification and acquired (May 24, 2018)
Research Institute founded and certified (May 21, 2018)
Seed& Pre-A investment completed (Dec 2017 / Jul 2018)
Selected TIPS program by the Ministry of SMEs and Startups (Dec 22, 2017)
Registered as R&D Special Zone (Gwangju Innopolis) Research Company (Nov 23, 2017)
Technology and patents transfer from Dankook Univ. (Oct 11, 2017)
Rznomics Inc. established (Aug 29, 2017)